Arbekacin

Synonym(s): ME1100

Class: Aminoglycoside

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-positive and Gram-negative bacteria
Description:	Semisynthetic, derived from dibekacin. Marketed in Japan for systemic use to treat MRSA infections, developed for inhalation in the US (since 2018)
Institute where first reported:	Meiji Seika Pharma
Year first mentioned:	1973
Highest developmental phase:	Phase 1 for inhalation (since 2013)
Development status:	Approved, off-patent

Chemical structure(s):
Canonical SMILES:	C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)N)O)NC(=O)[C@H](CCN)O)N)N
Isomeric SMILES:	C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N
InChI:	InChI=1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1
InChI Key:	MKKYBZZTJQGVCD-XTCKQBCOSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/68682

External links:
Guide to Pharmacology:	arbekacin
Main Source:	https://pubmed.ncbi.nlm.nih.gov/4782059/
Citation:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432132/